Pasadena, CA, United States of America

Mark Boldin

USPTO Granted Patents = 6 


Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2014-2019

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Mark Boldin

Introduction

Mark Boldin is a notable inventor based in Pasadena, California. He has made significant contributions to the field of biomedical research, particularly in the area of microRNA and its implications for treating various disorders. With a total of six patents to his name, Boldin's work has the potential to impact the treatment of inflammation and myeloproliferative disorders.

Latest Patents

Among his latest patents is a groundbreaking discovery related to microRNA inhibition for the treatment of inflammation and myeloproliferative disorders. This patent highlights the role of microRNA-155 in inflammation, hematopoiesis, and myeloproliferation. The findings suggest that dysregulation of microRNA-155 expression is linked to specific myeloproliferative disorders. The patent discloses methods and compositions for diagnosing and treating these disorders by modulating the expression levels of various genes, including Cutl1, Arntl, Picalm, Jarid2, PU.1, Csf1r, HIF1α, Sla, Cebpβ, and Bach1.

Career Highlights

Mark Boldin has had a distinguished career, working with prestigious institutions such as the California Institute of Technology and Yeda Research and Development Company. His research has focused on the molecular mechanisms underlying various diseases, contributing to advancements in therapeutic strategies.

Collaborations

Throughout his career, Boldin has collaborated with esteemed colleagues, including David Baltimore and Konstantin Taganov. These collaborations have further enriched his research and expanded the impact of his innovations.

Conclusion

Mark Boldin's contributions to the field of biomedical research, particularly through his patents on microRNA inhibition, demonstrate his commitment to advancing medical science. His work holds promise for improving treatment options for patients suffering from inflammation and myeloproliferative disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…